TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Concentration-time Curve of Metformin in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Empagliflozin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Metformin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Resting Heart Rate at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Resting Heart Rate at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Resting Heart Rate at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Preoperative Pressure Pain Threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality or severe intraventricular haemorrhage or periventricular leukomalacia
Endpoint domain: Mortality/survival
Primary endpoint: Half-life of the neonatal formulation of dobutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Frequency of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Parasite prevalence during the high transmission season among children <6 years old
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: P.falciparum infection incidence rate among individuals ≥3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dynamic changes in Global Longitudinal Strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: graft failure or death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With a rtPA Protocol Violation
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline of Fecal Bile Acid Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean difference between BSID-II Mental Development Index (MDI) and Bayley-III Cognitive Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent Patients Reaching the Defined Target Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uremic solute variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in employment and earnings
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Degree of Aortic Wall Injury (AWI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal tolerated and/or biologically active dose of Gemtuzumab Ozogamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for atrial fibrillation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: safety of selegiline
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: right ventricular and pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NYHA class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: procedural success
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of erectile dysfunction (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily number of times subject switches between activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater Reliability of Pupillary Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effective time window
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ICIQ-FLUTS total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean time to acquire images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of attempted studies with clinically useful images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood levels of persistent organic pollutants (POPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fecal excretion of persistent organic pollutants (POPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of ARIDA test device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of ARIDA test device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting heart rate variability (RMSSD index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUCt) for selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration at steady state (Cmax,ss) for selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pocket depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in provider knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in provider confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained Virological Response (SVR) at 24 Weeks Post Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Phase Half-Life (T1/2) of Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-Year Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: serum native thiol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum disulphide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum total thiol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent reduction in ST use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence from ST use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: State-Trait Anxiety Inventory for Children-State Form (STAIC-State)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Metabolic improvement of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemagglutination inhibiting antibodies (HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Platelet Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Patients With Local Control of Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Grade 2 and Greater Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Patient report of differences in the rates of initiation of discussions of PRI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of smoking quit attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of thrombi or spontaneous contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain as Assessed by the MOBID-2 Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicidal Attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinical signs of chronic periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in thyroid nodule volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood loss during laparoscopic myomectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD endoscopic index of severity (CDEIS) < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of complication related to the investigational device
Endpoint domain: Adverse events/effects
Primary endpoint: Cord blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Opioid Cessation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postinterventional bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Postinterventional occurrence of fistulas
Endpoint domain: Adverse events/effects
Primary endpoint: Early Phase Allergic Response
Endpoint domain: Adverse events/effects
Primary endpoint: Change in digestive discomfort symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Local Reactions After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Blood levels of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood levels of LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood levels of HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: End-systolic Elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants for Which Treatment Was Concluded to be Safe
Endpoint domain: Adverse events/effects
Primary endpoint: Change in overall symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbosacral nerve root function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to the 2009 Syncope Guidelines
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Peripheral Capillary Oxygen Saturation (SPO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovarian follicular development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: delay in rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: American Orthopedic Foot and Ankle Society - Hindfoot Score (AOFAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants That Demonstrated Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Days Receiving Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence of shoulder rotator cuff tear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain score at 24 hours post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in fasting serum TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Isometric Muscle Strength (Knee Extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isometric Muscle Strength (Knee Flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isometric Muscle Strength (Hip Abduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isometric Muscle Strength (Hip Adduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Handgrip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in Latency to Persistent Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants Who Experienced Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Interleukin 10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with hyposmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse reproductive outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Serum Alkaline Phosphatase (ALP) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HVPG change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold Rise of the VZV-Specific Immune Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Daily and Comfortable Wearing Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total opioid use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total cost of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of Hypoglycemic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tactile detection threshold of mechanoreceptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse plaque characteristics detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severity of illness associated with thyroid function (free T4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of non-maturation
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital Admission Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: intrinsic functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Any Severe Related TEAEs Per Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Related Serious TEAEs Per Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Any Related Serious TEAEs Per Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Virological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right Ventricular Ejection Fraction (RVEF %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Child development outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUCss,tau of D308
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,max of D308
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCss,tau of CKD-501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,max of CKD-501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: undetectable PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in RV/TLC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sternal stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of knowledge after intervention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pain score on the visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED revisit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in laryngeal movement during swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose postprandial levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Escape/elopement occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of frequency of micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of grade II or higher radiation epidermitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: failure rate of initial management strategy
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Social Anxiety Interaction Scale at 7 days
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline in Social Phobia Scale at 7 days
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Cognitive Fusion Questionnaire at 7 days
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wound reepithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lifting and Tightening of Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wrinkle Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HIV Positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral (ARV) initiation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Sinuses With Patency of Sinus Ostium After Sinuplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events Following Sinuplasty Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma Miss Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adenoma Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Apparent terminal disposition half-life t½
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of pathological Alarm Distress BaBy (ADBB) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SANS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from facial nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative change in cinacalcet dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrophage migration inhibitory factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exposure to BUP (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal Circumference Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expired Carbon Monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freeze / thaw survival rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes